Bristol-myers Squibb Compnay

Yunhui Zhang

Kenneth M Boy

Yong-Jin Wu

John E Macor

Jason T Goodrich

Lorin A Thompson, Iii

Jason M Guernon

Nicholas A Meanwell

Paul Michael Scola

Michael A Poss

David R Langley

Claudio Mapelli

Kevin W Gillman

Jianliang Shi

Richard Eric Olson

Li Xu

Dmitry S Zuev

Oak K Kim

B Narasimhulu Naidu

Makonen Belema

Li-Qiang Sun

Alicia Regueiro-Ren

Joanne J Bronson

Alain Martel

Eric P Gillis

Thomas W Hudyma

Yasutsugu Ueda

Van N Nguyen

Qian Zhao

Xiaofan Zheng

Eric Mull

Michael A Walker

Anne Marinier

John D Matiskella

Yuping Qiu

Margaret E Sorenson

Timothy P Connolly

Francis Beaulieu

Lawrence R Marcin

Amy Mae Bunker

David J Donnelly

Carl Ouellet

Mendi A Higgins

Stephan Roy

Xuejie Yang

Dane M Springer

Timothy D Johnson

Joonyoung Kim

Adrienne Pena

Christopher Zusi

M Nicholas Meanwell

Lorin A Thompson Iii

Lorin A Iii Thompson

Iii Lorin A Thompson

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Immunomodulators

The invention relates to the synthesis and use ofF-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.

PET-imaging immunomodulators

The present disclosure provides a series of compounds of the formula (I) 

Compounds for the reduction of &#x3b2;-amyloid production

Compounds of the formula (I) are provided, including pharmaceutically acceptable salts thereof: which modulate &#x3b2;-amyloid peptide (&#x3b2;-AP) production, and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Compounds for the reduction of beta-amyloid production

The present disclosure provides a series of compounds of the formula (I) which reduce &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Bicyclic compounds for the reduction of beta-amyloid production

There is provided a series of novel phenylcarboxyamides of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R, R, X and Y as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by &#x3b2;-secretase and, more specifically, inhibit the production of A&#x3b2;-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to &#x3b2;-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Phenylcarboxyamides as beta-secretase inhibitors

The present invention provides compounds of formula Ihaving potent antibiotic activity, including activity towards Gram-positive bacteria and mycobacteria.

O-derivatized nocathiacin derivatives

Compounds having the formula (I),and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, are useful as anti-inflammatory agents, in which R, R, and Rare hydrogen, halogen, alkyl, or perfluoroalkyl; Ris an optionally substituted alkyl or cycloalkyl group; X is a linker; A is an aryl, heteroaryl, heterocycle, cycloalkyl, or is absent; and Ris a substituent on A as defined in the specification.

Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same

HIV integrase inhibitors

Growing community of inventors

Glastonbury, CT, United States of America

Yunhui Zhang